## Karolinska Institutet <br> http://openarchive.ki.se <br> This is a Peer Reviewed Accepted version of the following article, accepted for publication in Cancer Research.

# Assessment of breast cancer risk factors reveals subtype heterogeneity 

Holm, Johanna; Eriksson, Louise; Ploner, Alexander; Eriksson, Mikael; Rantalainen, Mattias; Li, Jingmei; Hall, Per; Czene, Kamila

Cancer Res. 2017 Jul 1;77(13):3708-3717.
American Association for Cancer Research
http://doi.org/10.1158/0008-5472.CAN-16-2574
http://hdl.handle.net/10616/47145

If not otherwise stated by the Publisher's Terms and conditions, the manuscript is deposited under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives

License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

Online-only supplementary tables and figures:

1. Supplementary Table 1. Title: Cross-validated Confusion matrix for true vs. predicted subtypes in the subset of data with PAM50 subtypes available. Entries are percentual average cell counts across resamples.
2. Supplementary Table 2 Title: Case-only analysis with Luminal A as reference group: Genetic background risk.
3. Supplementary Table 3 Title: Case-only analysis with Luminal A as reference group: Reproductive risk factors.
4. Supplementary Table 4. Title: Case-only analysis with Luminal A as reference group: Bodyshape at age 18, Ever hormone replacement therapy (HRT) use, age at menarche, mammographic density (MD), benign breast disease (BBD).
5. Supplementary Table 5 Title: Risk of breast cancer overall and by subtype as defined by the St Gallen IHC proxy: Genetic background risk.
6. Supplementary Table 6 Title: Risk of breast cancer overall and by subtype as defined by the St Gallen IHC proxy: Reproductive risk factors.
7. Supplementary Table 7 Title: Risk for breast cancer overall and by subtype as defined by the St Gallen IHC proxy: Bodyshape at age 18, Ever hormone replacement therapy (HRT) use, age at menarche, mammographic density (MD), benign breast disease (BBD).

Supplementary table 1. Cross-validated confusion matrices for true vs. predicted subtypes in the subset of data with PAM50 subtypes available. Entries are percentual average cell counts across resamples.

| Predicted subtypes | True subtypes |  |  |  |  |
| ---: | ---: | ---: | ---: | ---: | :---: |
|  | Luminal A | Luminal B | HER2-overexpr. | Basal-like |  |
| Luminal A | 47.4 | 10.3 | 2.8 | 0.0 |  |
| Luminal B | 4.7 | 10.7 | 2.5 | 0.5 |  |
| HER2-overexpr. | 1.4 | 2.6 | 6.5 | 1.3 |  |
| Basal-like | 0.0 | 0.0 | 1.3 | 7.9 |  |
| By St Gallen |  |  |  |  |  |
| Luminal A | 31.9 | 4.7 |  |  |  |
| Luminal B | 21.7 | 19.1 | 0.9 | 0.0 |  |
| HER2-overexpr. | 0.0 | 0.0 | 5.5 | 0.9 |  |
| Basal-like | 0.4 | 0.0 | 4.7 | 0.4 |  |

Supplementary Table 2.Case-only analysis with Luminal A as reference group: Genetic background risk. Odds ratios with 95\% confidence intervals. Adjusted for born in Sweden or not, education level and age.

| Exposure |  | $\begin{gathered} \text { Luminal A } \\ (\mathrm{n}, \%) \end{gathered}$ | $\begin{aligned} & \text { Luminal B } \\ & (\mathrm{n}, \%) \end{aligned}$ | OR (95\% CI) Luminal B | HER2overexpressing ( $\mathrm{n}, \%$ ) | $\begin{gathered} \text { OR (95\% CI) } \\ \text { HER2 } \end{gathered}$ | $\begin{gathered} \text { Basal-like } \\ (\mathrm{n}, \%) \end{gathered}$ | OR (95\% CI) <br> Basal-like |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| BRCA mutation, self-reported | No (Ref.) | 1,505 (99\%) | 203 (99\%) | 1.00 (ref) | 234 (99\%) | 1.00 (ref) | 105 (85\%) | 1.00 (ref) |
|  | Yes | 17 (1\%) | 3 (1\%) | 1.05 (0.30-3.64) | 3 (1\%) | 0.99 (0.28-3.44) | 18 (15\%) | 11.13 (5.37-23.07) |
| Mother or Sister with Breast Cancer | No (Ref.) | 960 (80\%) | 659 (79\%) | 1.00 (ref) | 112 (82\%) | 1.00 (ref) | 169 (80\%) | 1.00 (ref) |
|  | Yes | 236 (20\%) | 174 (21\%) | 1.32 (0.95-1.82) | 24 (18\%) | 1.06 (0.76-1.97) | 42 (20\%) | 1.15 (0.75-1.76) |
| Polygenic Risk Score | $1^{\text {st }}$ quartile | 135 (15\%) | 88 (15\%) | 1.20 (0.78-1.84) | 28 (23\%) | 0.83 (0.55-1.25) | 36 (21\%) | 1.19 (0.71-2.01) |
|  | $2^{\text {nd }}$ quartile (Ref.) | 165 (19\%) | 121 (20\%) | 1.00 (ref) | 31 (26\%) | 1.00 (ref) | 42 (24\%) | 1.00 (ref) |
|  | $3{ }^{\text {rd }}$ quartile | 241 (27\%) | 159 (26\%) | 0.96 (0.63-1.44) | 29 (24\%) | 0.74 (0.51-1.07) | 46 (26\%) | 0.73 (0.44-1.24) |
|  | $4^{\text {th }}$ quartile | 242 (39\%) | 236 (39\%) | 0.65 (0.43-0.99) | 32 (27\%) | 0.49 (0.34-0.42) | 50 (29\%) | 0.48 (0.28-0.81) |
|  | Linear, per SD increase |  |  | 0.82 (0.71-0.95) |  | 0.78 (0.68-0.90) |  | 0.66 (0.55-0.80) |
| Polygenic Risk Score Weighted on ER - | $1^{\text {st }}$ quartile | 180 (20\%) | 123 (23\%) | 1.40 (0.91-2.14) | 22 (18\%) | 0.98 (0.64-1.49) | 31 (18\%) | 0.76 (0.42-1.37) |
|  | $2^{\text {nd }}$ quartile (Ref.) | 224 (25\%) | 123 (21\%) | 1.00 (ref) | 28 (23\%) | 1.00 (ref) | 37 (21\%) | 1.00 (ref) |
|  | $3{ }^{\text {rd }}$ quartile | 221 (25\%) | 166 (29\%) | 1.07 (0.70-1.64) | 33 (28\%) | 0.99 (0.67-1.46) | 43 (25\%) | 0.92 (0.55-1.55) |
|  | $4^{\text {th }}$ quartile | 258 (29\%) | 192 (28\%) | 1.10 (0.72-1.68) | 37 (31\%) | 1.20 (0.82-1.75) | 63 (36\%) | 1.13 (0.68-1.86) |
|  | Linear, per SD increase |  |  | 0.93 (0.80-1.08) |  | 1.07 (0.94-1.23) |  | 1.11 (0.92-1.33) |

Supplementary Table 3. Case-only analysis with Luminal A as reference group: Reproductive risk factors. Odds ratios with $95 \%$ confidence intervals.

| Exposure |  | $\begin{aligned} & \text { Luminal A } \\ & (\mathrm{n}, \%) \end{aligned}$ | Luminal B $(\mathrm{n}, \%)$ | OR (95\% CI) Luminal B | HER2overexpressing ( $\mathrm{n}, \%$ ) | OR (95\% CI) HER2 | Basal-like (n, \%) | OR (95\% CI) Basal-like |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Paritya | Nulliparous (ref) | 196 (16\%) | 152 (18\%) | 1.00 (ref) | 23 (17\%) | 1.00 (ref) | 32 (14\%) | 1.00 (ref) |
|  | 1-2 children | 785 (63\%) | 513 (597\%) | 0.81 (0.53-1.22) | 90 (65\%) | 1.06 (0.70-1.61) | 138 (62\%) | 1.49 (0.85-2.62) |
|  | >2 children | 265 (21\%) | 205 (24\%) | 0.99 (0.64-1.55) | 26 (19\%) | 1.02 (0.65-1.61) | 54 (24\%) | 1.66 (0.90-3.07) |
|  | Linear, per child increase |  |  | 1.06 (0.94-1.20) |  | 1.04 (0.92-1.17) |  | 1.14 (0.97-1.33) |
| Age at first birthb | <30 (ref) | 751 (27\%) | 499 (70\%) | 1.00 (ref) | 74 (64\%) | 1.00 (ref) | 131 (69\%) | 1.00 (ref) |
|  | $>=30$ | 278 (73\%) | 215 (30\%) | 1.07 (0.75-1.52) | 41 (36\%) | 1.00 (0.72-1.39) | 58 (31\%) | 0.92 (0.60-1.42) |
| Breastfeeding, parous women onlyc | Ever (ref) | 999 (96\%) | 683 (96\%) | 1.00 (ref) | 115 (99\%) | 1.00 (ref) | 175 (93\%) | 1.00 (ref) |
|  | Never | 44 (4\%) | 29 (4\%) | 1.15 (0.54-2.47) | 1 (1\%) | 0.57 (0.22-1.44) | 13 (7\%) | 2.76 (1.37-5.56) |
| Breastfeeding, including all womenc $_{c}$ | Nulliparous (ref) | 196 (16\%) | 152 (18\%) | 1.00 (ref) | 23 (17\%) | 1.00 (ref) | 32 (14\%) | 1.00 (ref) |
|  | Parous, never breastfed | 44 (4\%) | 29 (3\%) | 0.93 (0.41-2.14) | 1 (1\%) | 0.61 (0.22-1.64) | 13 (6\%) | 4.17 (1.79-9.73) |
|  | Parous, breastfed $>0-1.5$ years | 734 (59\%) | 466 (54\%) | 0.78 (0.51-1.19) | 81 (58\%) | 1.06 (0.70-1.62) | 119 (54\%) | 1.53 (0.86-2.72) |
|  | Parous, breastfed >1.5 years | 265 (21\%) | 217 (25\%) | 0.93 (0.56-1.53) | 34 (25\%) | 1.06 (0.64-1.75) | 56 (26\%) | 1.37 (0.70-2.68) |

a = Parity adjusted for born in Sweden or not, age, education level, breastfeeding, age at first birth and BMI.
$b=$ Age at first birth adjusted for born in Sweden or not, age, education level, breastfeeding, parity and BMI.
$d=$ Breastfeeding adjusted for born in Sweden or not, age, education level, parity, age at first birth and BMI.

Supplementary Table 4. Case-only analysis with Luminal A as reference group: Ever hormone replacement therapy (HRT) use, age at menarche, mammographic density (MD), Bodyshape at age 18, benign breast disease (BBD). Odds ratios with $95 \%$ confidence intervals. SD $=$ standard deviation.

| Exposure |  | Luminal A (n, \%) | Luminal B ( $\mathrm{n}, \%$ ) | $\begin{gathered} \hline \text { OR (95\% CI) } \\ \text { Luminal B } \end{gathered}$ | HER2overexpressing ( $\mathrm{n}, \%$ ) | OR (95\% CI) HER2 | $\begin{gathered} \hline \text { Basal-like } \\ (\mathrm{n}, \%) \end{gathered}$ | OR ( $95 \% \mathrm{CI}$ ) Basal-like |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HRT usea | Never | 677 (63\%) | 498 (66\%) | 1.00 (ref) | 85 (71\%) | 1.00 (ref) | 144 (72\%) | 1.00 (ref) |
|  | Ever | 395 (37\%) | 257 (34\%) | 0.68 (0.47-0.96) | 35 (29\%) | 0.83 (0.60-1.15) | 56 (28\%) | 0.74 (0.47-1.19) |
| Menarche ${ }_{\text {a }}$ | Linear, per year increase | 1,736 | 239 | 1.01 (0.92-1.10) | 265 | 1.07 (0.98-1.17) | 149 | 1.07 (0.96-1.20) |
| Absolute Mammographic Densitya | Linear, per SD increase | 1,240 | 160 | 1.03 (0.87-1.22) | 171 | 0.96 (0.81-1.14) | 95 | 0.89 (0.71-1.13) |
| Somatotype at age 18b | Linear, Increasingly endomorph | 1,739 | 242 | 1.00 (0.88-1.12) | 265 | 0.97 (0.86-1.09) | 149 | 1.06 (0.91-1.23) |
| Benign Breast Disease, <br> Non-proliferative lesionsc | No | 1,242 (91\%) | 857 (93\%) | 1.00 (ref) | 129 (90\%) | 1.00 (ref) | 221 (94\%) | 1.00 (ref) |
|  | Yes | 76 (6\%) | 65 (7\%) | 1.15 (0.68-1.96) | 15 (10\%) | 1.57 (0.99-2.48) | 15 (6\%) | 0.78 (0.36-1.76) |
| Benign Breast Disease, Proliferative lesions nonatypic | No | 1,268 (96\%) | 899 (97\%) | 1.00 (ref) | 140 (97\%) | 1.00 (ref) | 226 (96\%) | 1.00 (ref) |
|  | Yes | 50 (4\%) | 23 (3\%) | 0.66 (0.28-1.53) | 4 (3\%) | 0.88 (0.43-1.79) | 10 (4\%) | 0.88 (0.34-2.23) |

a = Adjusted for born in Sweden or not, age, education level, parity and BMI.
$\mathrm{b}=$ Adjusted for born in Sweden or not, age, age at menarche and education level.
c = Adjusted for born in Sweden or not, age, education level, parity and BMI.

Supplementary Table 5. Risk of breast cancer overall and by subtype as defined by the St Gallen IHC proxy: Genetic background risk. Odds ratios with $95 \%$ confidence intervals, for controls as reference group. Adjusted for born in Sweden or not, education level and age.

| Exposure |  | Controls $(n, \%)$ | $\begin{gathered} \text { Luminal A } \\ (\mathrm{n}, \%) \end{gathered}$ | OR (95\% CI) Luminal A | $\begin{gathered} \text { Luminal B } \\ (\mathrm{n}, \%) \end{gathered}$ | OR (95\% CI) Luminal B | HER2overexpressing ( $\mathrm{n}, \%$ ) | OR (95\% CI) HER2 | Basal-like ( $\mathrm{n}, \%$ ) | OR (95\% CI) Basal-like | P <br> heterogen eity |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Mother or Sister with Breast Cancer | No (Ref.) | 13,379 (86\%) | 960 (80\%) | 1.00 (ref) | 659 (79\%) | 1.00 (ref) | 112 (82\%) | 1.00 (ref) | 169 (80\%) | 1.00 (ref) |  |
|  | Yes | 2,083 (14\%) | 236 (20\%) | 1.55 (1.33-1.80) | 174 (21\%) | 1.67 (1.40-1.99) | 24 (18\%) | 1.40 (0.90-2.19) | 42 (20\%) | 1.63 (1.16-2.30) | 0.85 |
| Polygenic Risk Score | $1^{\text {st }}$ quartile | 1,521 (28\%) | 135 (15\%) | 0.81 (0.63-1.04) | 88 (15\%) | 0.73 (0.54-0.97) | 28 (23\%) | 0.90 (0.53-1.51) | 36 (21\%) | 0.85 (0.54-1.34) | 0.86 |
|  | $2^{\text {nd }}$ quartile (Ref.) | 1,449 (27\%) | 165 (19\%) | 1.00 (ref) | 121 (20\%) | 1.00 (ref) | 31 (26\%) | 1.00 (ref) | 42 (24\%) | 1.00 (ref) |  |
|  | $3^{\text {rd }}$ quartile | 1326(24\%) | 241 (27\%) | 1.66 (1.33-2.08) | 159 (26\%) | 1.50 (1.16-1.93) | 29 (24\%) | 1.03 (0.62-1.74) | 46 (26\%) | 1.23 (0.80-1.89) | 0.26 |
|  | $4^{\text {th }}$ quartile | 1,129 (21\%) | 242 (39\%) | 2.90 (2.34-3.59) | 236 (39\%) | 2.73 (2.13-3.46) | 32 (27\%) | 1.37 (0.83-2.27) | 50 (29\%) | 1.62 (1.06-2.46) | 0.005 |
|  | Linear, per SD increase |  |  | 1.70 (1.57-1.84) |  | 1.69 (1.54-1.85) |  | 1.24 (1.03-1.50) |  | 1.26 (1.08-1.57) | <0.0001 |
| Polygenic Risk Score Weighted on ER - | $1^{\text {st }}$ quartile | 1,453 (27\%) | 180 (20\%) | 0.81 (0.65-1.01) | 123 (23\%) | 1.00 (0.76-1.30) | 22 (18\%) | 0.79 (0.45-1.38) | 31 (18\%) | 0.83 (0.51-1.35) | 0.62 |
|  | $2^{\text {nd }}$ quartile (Ref.) | 1,392(26\%) | 224 (25\%) | 1.00 (ref) | 123 (21\%) | 1.00 (ref) | 28 (23\%) | 1.00 (ref) | 37 (21\%) | 1.00 (ref) |  |
|  | $3^{\text {rd }}$ quartile | 1,336 (25\%) | 221 (25\%) | 1.04 (0.84-1.48) | 166 (29\%) | 1.42 (1.10-1.83) | 33 (28\%) | 1.24 (0.75-2.08) | 43 (25\%) | 1.22 (0.78-1.91) | 0.23 |
|  | $4^{\text {th }}$ quartile | 1,244 (23\%) | 258 (29\%) | 1.32 (1.07-1.62) | 192 (28\%) | 1.77 (1.38-2.27) | 37 (31\%) | 1.50 (0.91-2.47) | 63 (36\%) | 1.93 (1.27-2.93) | 0.14 |
|  | Linear, per SD increase |  |  | 1.21 (1.12-1.31) |  | 1.31 (1.20-1.43) |  | 1.34 (1.11-1.60) |  | 1.41 (1.21-1.64) | 0.20 |

Supplementary Table 6. Risk of breast cancer overall and by subtype as defined by the St Gallen IHC proxy: Reproductive risk factors. Odds ratios with $95 \%$ confidence intervals, for controls as reference group.

| Exposure |  | Controls (n, \%) | $\begin{gathered} \text { Luminal A } \\ (n, \%) \end{gathered}$ | OR (95\% CI) Luminal A | $\begin{aligned} & \text { Luminal B } \\ & (\mathrm{n}, \%) \end{aligned}$ | OR (95\% CI) Luminal B | HER2overexpressing ( $\mathrm{n}, \%$ ) | $\begin{gathered} \hline \text { OR (95\% CI) } \\ \text { HER2 } \end{gathered}$ | Basal-like ( $\mathrm{n}, \%$ ) | OR (95\% CI) Basal-like | $P$ heterogen eity |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Paritya | Nulliparous (ref) | 1,931 (12\%) | 196 (16\%) | 1.00 (ref) | 152 (18\%) | 1.00 (ref) | 23 (17\%) | 1.00 (ref) | 32 (14\%) | 1.00 (ref) |  |
|  | 1-2 children | 10,094 (63\%) | 785 (63\%) | 0.73 (0.61-0.88) | 513 (597\%) | 0.58 (0.47-0.72) | 90 (65\%) | 0.61 (0.36-1.06) | 138 (62\%) | 0.91 (0.59-1.40) | 0.20 |
|  | >2 children | 3,914(25\%) | 265 (21\%) | 0.62 (0.50-0.76) | 205 (24\%) | 0.62 (0.49-0.78) | 26 (19\%) | 0.48 (0.26-0.86) | 54 (24\%) | 0.91 (0.57-1.44) | 0.35 |
|  | Linear, per child increase |  |  | 0.85 (0.81-0.90) |  | 0.88 (0.82-0.94) |  | 0.82 (0.69-0.97) |  | 0.97 (0.86-1.10) |  |
| Age at first birthb | $<30$ (ref) | 9,851 (74\%) | 751 (27\%) | 1.00 (ref) | 499 (70\%) | 1.00 (ref) | 74 (64\%) | 1.00 (ref) | 131 (69\%) | 1.00 (ref) |  |
|  | $>=30$ | 3,448 (26\%) | 278 (73\%) | 1.22 (1.05-1.43) | 215 (30\%) | 1.46 (1.22-1.45) | 41 (36\%) | 1.52 (0.99-2.30) | 58 (31\%) | 1.28 (0.91-1.80) | 0.44 |
| Breastfeeding ${ }_{c}$, parous women only | Ever (ref) | 13,583 (97\%) | 999 (96\%) | 1.00 (ref) | 683 (96\%) | 1.00 (ref) | 115 (99\%) | 1.00 (ref) | 175 (93\%) | 1.00 (ref) |  |
|  | Never | 367 (3\%) | 44 (4\%) | 1.48 (1.06-2.07) | 29 (4\%) | 1.52 (1.02-2.27) | 1 (1\%) | 0.36 (0.05-2.58) | 13 (7\%) | 3.23 (1.79-5.80) | 0.06 |
| Breastfeedingc, including all women | Nulliparous (ref) | 1,931(12\%) | 196 (16\%) | 1.00 (ref) | 152 (18\%) | 1.00 (ref) | 23 (17\%) | 1.00 (ref) | 32 (14\%) | 1.00 (ref) |  |
|  | Parous, never breastfed | 367 (2\%) | 44 (4\%) | 1.09 (0.75-1.57) | 29 (3\%) | 0.89 (0.57-1.38) | 1 (1\%) | 0.21 (0.03-1.62) | 13 (6\%) | 2.95 (1.47-5.90) | 0.009 |
|  | Parous, breastfed $>0-1.5$ years | 9,148 (58\%) | 734 (59\%) | 0.75 (0.62-0.91) | 466 (54\%) | 0.58 (0.46-0.72) | 81 (58\%) | 0.63 (0.36-1.09) | 119 (54\%) | 0.92 (0.59-1.43) | 0.15 |
|  | Parous, breastfed $>1.5$ years | 4,435 (28\%) | 265 (21\%) | 0.64 (0.51-0.80) | 217 (25\%) | 0.59 (0.45-0.76) | 34 (25\%) | 0.55 (0.29-1.06) | 56 (26\%) | 0.86 (0.51-1.44) | 0.60 |

a = Adjusted for born in Sweden or not, age, education level, breastfeeding, age at first birth and BMI.
$b=$ Adjusted for born in Sweden or not, age, education level, breastfeeding, parity and BMI.
$\mathrm{c}=$ Adjusted for born in Sweden or not, age, education level, parity, age at first birth and BMI.

Supplementary Table 7. Risk for breast cancer overall and by subtype as defined by the St Gallen IHC proxy: Bodyshape at age 18, Ever hormone replacement therapy (HRT) use, age at menarche, mammographic density (MD), benign breast disease (BBD). Odds ratios with $95 \%$ confidence intervals, for controls as reference group. $\mathrm{SD}=$ standard deviation.

| Exposure |  | Controls | $\begin{gathered} \text { Luminal A } \\ (\mathrm{n}, \%) \end{gathered}$ | OR (95\% CI) Luminal A | $\begin{gathered} \text { Luminal B } \\ (\mathrm{n}, \%) \end{gathered}$ | OR (95\% CI) Luminal B | HER2overexpressing ( $\mathrm{n}, \%$ ) | $\begin{gathered} \text { OR (95\% CI) } \\ \text { HER2 } \end{gathered}$ | Basal-like ( n , \%) | OR (95\% CI) <br> Basal-like | P heterogeneity |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HRT usea | Never | 10,922 (75\%) | 677 (63\%) | 1.00 (ref) | 498 (66\%) | 1.00 (ref) | 85 (71\%) | 1.00 (ref) | 144 (72\%) | 1.00 (ref) |  |
|  | Ever | 3,703 (25\%) | 395 (37\%) | 1.39 (1.21-1.59) | 257 (34\%) | 1.32 (1.11-1.46) | 35 (29\%) | 1.19 (0.78-1.82) | 56 (28\%) | 1.24 (0.89-1.73) | 0.84 |
| Menarchea | Linear, per year increase | 15,465 | 1,193 | 0.93 (0.89-0.97) | 836 | 0.96 (0.91-1.00) | 132 | 1.01 (0.90-1.14) | 216 | 1.01 (0.92-1.10) | 0.23 |
| Absolute Mammographic | Linear, per SD increase | 14,184 | 869 | 1.71 (1.61-1.82) | 569 | 1.69 (1.57-1.81) | 88 | 1.64 (1.39-1.95) | 137 | 1.63 (1.41-1.87) | 0.88 |
| Densitya |  |  |  |  |  |  |  |  |  |  |  |
| Somatotype at age 18b | Linear, Increasingly endomorph | 15,478 | 1,194 | 0.94 (0.89-0.99) | 840 | 0.91 (0.85-0.97) | 133 | 0.80 (0.68-0.94) | 216 | 1.03 (0.92-1.17) | 0.06 |
| Benign Breast <br> Disease ${ }_{\mathrm{c}}$, Nonproliferative lesions | No | 14,922 (94\%) | 1,242 (91\%) | 1.00 (ref) | 857 (93\%) | 1.00 (ref) | 129 (90\%) | 1.00 (ref) | 221 (94\%) | 1.00 (ref) |  |
|  | Yes | 1,023 (6\%) | 76 (6\%) | 0.81 (0.62-1.04) | 65 (7\%) | 1.16 (0.89-1.50) | 15 (10\%) | 1.80 (1.05-3.11) | 15 (6\%) | 1.01 (0.59-1.75) | 0.03 |
| Benign Breast | No | 15,566 (98\%) | 1,268 (96\%) | 1.00 (ref) | 899 (97\%) | 1.00 (ref) | 140 (97\%) | 1.00 (ref) | 226 (96\%) | 1.00 (ref) |  |
| Diseasec, Proliferative lesions non-atypic |  |  |  |  |  |  |  |  |  |  |  |
|  | Yes | 379 (2\%) | 50 (4\%) | 1.80 (1.32-2.46) | 23 (3\%) | 1.20 (0.78-1.84) | 4 (3\%) | 1.28 (0.47-3.49) | 10 (4\%) | 1.76 (0.90-3.46) | 0.43 |

a = Adjusted for born in Sweden or not, age, education level, parity and BMI.
$b=$ Adjusted for born in Sweden or not, age, age at menarche and education level.
$\mathrm{c}=$ Adjusted for born in Sweden or not, age, education level, parity and BMI.

